AACR Annual Meeting 2018 Recap

Share this Post:

AACR’s Annual Meeting brings us the latest and best in cancer science and medicine from institutions all over the world. This year’s meeting, held earlier this month in Chicago, did not disappoint. A few of our key takeaways included:

  • The “omics” approach have given us countless methods to evaluate subsets of patient response profiles, but we still don’t have a reliable predictive test for the vast majority of patients. We need to go back to the foundation and study the immune system and tumor tissue to develop better predictive tests to improve patient response.
  • There is excitement about the application of AI to the pathology space to advance the understanding of complex immune responses in cancer cells and serve as a guided tool for pathologists. Flagship is excited to apply these advancements in machine learning and AI to our digital analysis tools.
  • Multiplexing, combination studies and the development of predictive biomarkers beyond PD-LI were consistent themes. Drug developers are struggling with how to translate the scores of data produced by these approaches into actionable insight. Flagship has developed tools to translate these complex data sets into actionable approaches.

Flagship’s cTA platform applies computational tissue analysis to data and images to deliver an immune response profile with sufficient breadth, depth and speed to support predictive medicine approaches for your drug.

We were proud to present four scientific posters at AACR demonstrating how our cTA platform delivers this actionable insight. Please follow these links for full poster content posted on Flagship’s Resources page.